Developing innovative solutions to debilitating diseases

AdAlta’s i-body® drug discovery platform goes where antibodies do not, to create new options for debilitating diseases

  • Using i-bodies – with antibody features at a fraction of the size
  • Developing next generation protein and cell therapies – focused on fibrosis and immuno-oncology
  • Lead asset AD-214 – first in class product for treating fibrotic diseases
  • i-CAR-T cell therapies (reprogramming immune cells) – providing new hope for patients with solid tumours
  • i-PET imaging – helping cancer patients know early if their immunotherapy is working

More Info


More Info

Please join our mailing list for
more information and updates

Subscribe here

Investor Hub